| D009369 |
Neoplasms |
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. |
Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant |
|
| D005472 |
Fluorouracil |
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. |
5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000964 |
Antimetabolites, Antineoplastic |
Antimetabolites that are useful in cancer chemotherapy. |
Antineoplastic Antimetabolites |
|
| D016903 |
Drug Monitoring |
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. |
Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug |
|
| D017322 |
Clinical Trials, Phase II as Topic |
Works about studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the U.S. and in other countries. |
Drug Evaluation, FDA Phase 2 as Topic,Drug Evaluation, FDA Phase II as Topic,Evaluation Studies, FDA Phase 2 as Topic,Evaluation Studies, FDA Phase II as Topic |
|
| D017326 |
Clinical Trials, Phase III as Topic |
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries. |
Clinical Trials, Phase 3 as Topic,Drug Evaluation, FDA Phase 3 as Topic,Drug Evaluation, FDA Phase III as Topic,Evaluation Studies, FDA Phase 3 as Topic,Evaluation Studies, FDA Phase III as Topic |
|
| D042943 |
Dihydrouracil Dehydrogenase (NADP) |
An oxidoreductase involved in pyrimidine base degradation. It catalyzes the catabolism of THYMINE; URACIL and the chemotherapeutic drug, 5-FLUOROURACIL. |
Dihydropyrimidine Dehydrogenase,Dihydrothymine Dehydrogenase (NADP),Dehydrogenase, Dihydropyrimidine |
|
| D054067 |
Dihydropyrimidine Dehydrogenase Deficiency |
An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity. |
DPD Deficiency,Dihydropyrimidinuria,Familial Pyrimidemia,Familial Pyrimidinemia,Hereditary Thymine-Uraciluria,Pyrimidinemia, Familial,Thymine-Uraciluria, Hereditary,DPD Deficiencies,Deficiencies, DPD,Deficiencies, Dihydropyrimidine Dehydrogenase,Deficiency, DPD,Deficiency, Dihydropyrimidine Dehydrogenase,Dehydrogenase Deficiencies, Dihydropyrimidine,Dehydrogenase Deficiency, Dihydropyrimidine,Dihydropyrimidine Dehydrogenase Deficiencies,Dihydropyrimidinurias,Familial Pyrimidemias,Familial Pyrimidinemias,Hereditary Thymine Uraciluria,Hereditary Thymine-Uracilurias,Pyrimidemia, Familial,Pyrimidemias, Familial,Pyrimidinemias, Familial,Thymine Uraciluria, Hereditary,Thymine-Uracilurias, Hereditary |
|
-transparent.png){kind=logo}
